Calidi Biotherapeutics Q4 EPS (0.27) Down From ($0.23) YoY
Aardvark Therapeutics FY24 EPS (5.15) Down From ($1.82) YoY
Dare Bioscience GAAP EPS of -$0.48 Misses by $0.13, Revenue of $0.01M Misses by $1.04M
Wall Street Rallied to End Higher After Earlier Losses Pushed the S&P 500 to a 6-month Low
Connect Biopharma Reports Data From Global Phase 2 Trial Of Rademikibart In Patients With Moderate-To-Severe Uncontrolled Asthma
Rani Therapeutics Hldgs Q4 2024 GAAP EPS $(0.27) Misses $(0.25) Estimate